白蛋白结合型紫杉醇联合顺铂在初治局部晚期食管鳞状细胞癌中的应用效果分析  

Analysis of the Application Effect of Albumin-bound Paclitaxel Combined with Cisplatin in the Initial Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

作　　者：高莉莉[1] GAO Lili(Department of Oncology,Funing County People's Hospital,Funing 224400,Jiangsu,China)

机构地区：[1]阜宁县人民医院肿瘤科,江苏阜宁224400

出　　处：《中外医疗》2024年第19期107-110,共4页China & Foreign Medical Treatment

摘　　要：目的 探讨白蛋白结合型紫杉醇联合顺铂治疗方案在初治局部晚期食管鳞状细胞癌中的应用效果。方法 回顾性选取2021年1月—2023年3月阜宁县人民医院肿瘤科收治的62例局部晚期食管鳞状细胞癌患者的临床资料,根据不同的治疗方案分为参照组和治疗组,各31例。参照组接受紫杉醇联合顺铂化疗,治疗组接受白蛋白结合型紫杉醇联合顺铂化疗。比较两组患者疗效、肿瘤标志物、不良反应发生率。结果 治疗组治疗总有效率(83.67%)高于参照组(61.29%),差异有统计学意义(χ^(2)=3.971,P=0.046)。化疗前,两组患者肿瘤标志物水平对比,差异无统计学意义(P>0.05);化疗后,治疗组癌胚抗原、糖类抗原19-9、鳞状细胞癌抗原等肿瘤标志物水平低于参照组,差异有统计学意义(t=5.314、3.880、14.449,P均<0.001)。治疗组肌痛(25.81%)、骨髓抑制(32.26%)的发生率显著低于参照组(51.61%、61.29%),差异有统计学意义(χ^(2)=4.351、5.247,P均<0.05)。结论 白蛋白结合型紫杉醇联合顺铂治疗方案用于初治局部晚期食管鳞状细胞癌中疗效和安全性显著,可降低肿瘤标志物水平,应用价值显著。Objective To explore the application effect of albumin bound paclitaxel combined with cisplatin in the ini-tial treatment of locally advanced esophageal squamous cell carcinoma.Methods The clinical data of 62 patients with locally advanced esophageal squamous cell carcinoma admitted to the Oncology Department of Funing County People's Hospital from January 2021 to March 2023 were retrospectively selected.According to different treatment options,they were divided into reference group and treatment group,31 cases each.The reference group received paclitaxel combined with cisplatin chemotherapy,and the treatment group received albumin-bound paclitaxel combined with cis-platin chemotherapy.The efficacy,tumor markers and incidence of adverse effects were compared between patients in two groups.Results The effective rate of the treatment group(83.67%)was higher than that of the reference group(61.29%),and the difference was statistically significant(χ^(2)=3.971,P=0.046).Before chemotherapy,there was no sig-nificant difference in the level of tumor markers between the two groups(P>0.05).After chemotherapy,the levels of tu-mor markers such as carcinoembryonic antigen,carbohydrate antigen 19-9 and squamous cell carcinoma antigen in the treatment group were lower than those in the reference group,and the differences were statistically significant(t=5.314,3.880,14.449,all P<0.001).The incidence of myalgia(25.81%)and bone marrow suppression(32.26%)in the treatment group was significantly lower than that in the control group(51.61%,61.29%),the differences were statisti-cally significant(χ^(2)=4.351,5.247,both P<0.05).Conclusion The combination of albumin bound paclitaxel and cispla-tin has significant efficacy and safety in the initial treatment of locally advanced esophageal squamous cell carcinoma,and can reduce the level of tumor markers.Its application value is significant.

关 键 词：食管鳞状细胞癌 白蛋白结合型紫杉醇 顺铂 

分 类 号：R735.1[医药卫生—肿瘤]